NovoCure Limited
NVCR
$12.43
$0.524.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.27% | 11.46% | -40.02% | 38.22% | 41.87% |
| Total Depreciation and Amortization | 20.50% | 18.12% | 19.74% | -12.31% | 5.03% |
| Total Amortization of Deferred Charges | -- | -- | 12.06% | -- | -- |
| Total Other Non-Cash Items | 7.77% | -26.64% | 1,076.74% | 7.93% | -14.94% |
| Change in Net Operating Assets | -296.54% | -2.80% | -79.20% | 164.32% | 62.75% |
| Cash from Operations | -826.51% | -12.96% | 76.29% | 153.72% | 92.44% |
| Capital Expenditure | 52.07% | 9.95% | -31.10% | -47.29% | -65.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 111.42% | -98.40% | -112.60% | -14.83% | -5,110.94% |
| Cash from Investing | 109.61% | -102.63% | -122.55% | -40.94% | -2,594.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -430,333.33% |
| Issuance of Common Stock | -27.84% | 2,363.38% | 40.58% | -91.46% | -55.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.27% | 2,363.38% | 40.58% | -91.46% | 1,063.92% |
| Foreign Exchange rate Adjustments | 444.16% | 505.36% | -164.00% | 189.69% | -492.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.86% | -117.07% | -126.85% | 2,213.65% | -891.32% |